Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali.

@article{Lyke2004IncidenceOS,
  title={Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali.},
  author={Kirsten E. Lyke and Alassane Dicko and Abdoulaye Kassoum Kone and D. Coulibaly and Ando B. Guindo and Yacouba Cissoko and Karim Traore and Christopher V. Plowe and Ogobara K. Doumbo},
  journal={Vaccine},
  year={2004},
  volume={22 23-24},
  pages={3169-74}
}
Potential endpoints for blood stage malaria vaccine efficacy trials include uncomplicated malaria disease, which is hard to differentiate from other febrile illnesses, and mortality, which requires prohibitively large sample sizes. Strictly defined severe malaria predicts malaria-associated mortality where case fatality rates are known. To assess the suitability of severe malaria as a trial endpoint, we conducted a census in 1999 and measured the incidence of severe malaria from 1999 to 2001 in… CONTINUE READING

From This Paper

Topics from this paper.
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…